Challenges
Datasets
Workspaces
Papers
Discussions
Leaderboard
Log inSign up
Challenges
Datasets
Workspaces
Papers
Discussions
Leaderboard
Blog
Job Board
Q3AS

© 2026 Aqora Quantum S.A.S.

TermsPrivacyLegal Notice

International Conference on Next Generation Computing Applications (NextComp)

Protein-Ligand Binding Energy Calculation Using Quantum Approximate Optimization Technique

Dassen Sathan, Shakuntala Baichoo

Published Jul 1, 2026• 0 citations
Publisher

Abstract

Drug discovery is a resource-intensive process that often requires years of research and incurs high computational costs. Although classical machine learning (ML) has enhanced aspects of this process, its scalability is constrained by the exponential complexity of molecular interactions. Quantum computing (QC), with its inherent capabilities of superposition and entanglement, presents a transformative opportunity to overcome these limitations. Here, we introduce a novel Quantum Approximate Optimization Algorithm (QAOA)-based framework designed to efficiently compute protein-ligand binding energies which is a pivotal metric in rational drug design and precision medicine. By reformulating the binding energy problem as a MaxCut optimization, our approach achieves remarkable accuracy, with deviations of only ± 0.5kcal/mol relative to established classical methods such as funnel metadynamics. Furthermore, we demonstrate the robustness of the algorithm across various ligand topologies and protein conformations, highlighting its potential for scalable quantumaccelerated drug screening. This study advances the application of near-term quantum algorithms in computational chemistry and lays the foundation for future QC-driven breakthroughs in biomedical research. Our findings underscore the feasibility of quantumenhanced drug discovery, offering a pathway to significantly reduce the development timelines and costs while improving therapeutic precision.

DOI
10.1109/nextcomp70574.2026.11707993

Related papers

Computational Precision Medicine Through Quantum-Enhanced Molecular Modeling

Chidi Ijeoma Nosiri, Paul Okoli, Echerou Leonard Nnadi +2 more

The exorbitant costs, protracted timelines, and elevated attrition rates associated with traditional drug-discovery pipelines underscore the pressing necessity for computational frameworks that can elucidate biomolecular interactions with quantum-level precision and practical scalability. This study introduces a Hybrid Quantum Classical (HQC) framework that combines quantum variational algorithms, classical molecular dynamics, and quantum-assisted machine-learning optimization into a single drug-screening workflow. It builds on the basic idea of Quantum Molecular Simulation (QMS). In the suggested design, quantum processors are used to selectively fix high-fidelity electronic interactions in reactive binding sites, while classical engines model the large-scale conformational dynamics of biomolecular environments. An adaptive quantum-machine-learning layer speeds up convergence even more by learning how structure and energy are related from quantum-refined descriptors. Benchmark tests against oncogenic targets like EGFR, BCR-ABL1, and p53 show that our method is up to 27% more accurate at converging binding energy and takes 4.3 times less time to compute than standard density-functional-theory and standalone QMS methods. The HQC framework makes quantum drug simulation possible for real-world drug discovery by reducing the limitations of current quantum hardware while keeping electronic-scale accuracy. This study demonstrates that hybrid quantum-classical modeling is a scalable and hardware-compatible approach for advancing next-generation computational drug design and precision therapeutics.

Iconic Research and Engineering Journals•Jul 31, 2023•0 citations

Quantum Assisted Drug Discovery in Human Beings

B S Anupama, Amrit S R, A Chetan Kumar

The large search space and the challenge of accurately simulating quantum-level molecular interactions are the fundamental causes of the delayed, complicated, and costly process of discovering new medications. The effectiveness of conventional computational techniques, including molecular docking and molecular dynamics, to assess molecular characteristics and provide highly accurate drug candidate predictions is constrained. This paper presents a Quantum-Assisted Drug Discovery Simulation framework that combines cutting-edge quantum computing algorithms, specifically the Quantum Approximate Optimization Algorithm (QAOA) and the Variational Quantum Eigensolver (VQE), with traditional molecular docking tools like RDKit and AutoDock. The system uses these quantum algorithms to perform very accurate Quantum Refinement on the most potential therapeutic protein poses found by classical identification. This hybrid approach seeks to optimize drug-protein interactions more quickly, speed up early-stage drug discovery, and create opportunities for less costly, more accurate medical research, even though a combination of quantum and classical calculations allows more accurate prediction of molecular energies and binding affinities.

International Conference on Knowledge Engineering and Communication Systems (ICKECS)•Apr 24, 2026•0 citations

Quantum Computing in Drug Discovery

Deepa Priya.V, J. Gnana Jersha, G. Madhubhavani +3 more

The drug discovery process has always been a problem for the pharmaceutical industry’s low rates of success, high expenses, and long-time frames. Quantum computing (QC) is being touted as a revolutionary advancement because of its unparalleled speed to carry out intricate multi molecular simulation and optimization. Unfortunately, its practical use has been suppressed due to the absence of proper hardware and the integration problems with traditional systems. Our solution is a quantum-classical pipeline for drug discovery. This pipeline utilizes machine learning (ML) for protein-ligand binding, drug property optimization, and even de novo drug design. In this paper we describe the pipeline, its components, the way it operates using NISQ devices, and the improvements it has in terms of accuracy and scalability (93.5% vs 78.2%) when compared with classical methods. Finally, we summarize how this can aid in modern drug discovery. It could significantly decrease the cost and timeline for pharmaceutical innovations.

International Research Journal on Advanced Engineering and Management (IRJAEM)•Mar 22, 2025•3 citations

Quantum-Enhanced Computational Drug Discovery: Leveraging Variational Quantum Algorithms for Accurate Binding Affinity Prediction and Lead Optimization in Complex Biological Targets

Hande Selvi Yanık

Accurate prediction of binding affinities and efficient lead optimization remain central challenges in computational drug discovery, particularly for complex biological targets characterized by rugged energy landscapes, conformational heterogeneity, and high-dimensional interaction spaces. Classical computational methods—such as molecular docking, force-field–based simulations, and deep learning models—have made substantial progress, yet they often struggle to capture quantum-mechanical effects and long-range correlations critical to molecular recognition. This study explores a quantum-enhanced framework that integrates Variational Quantum Algorithms (VQAs), quantum-inspired Hamiltonian modeling, and hybrid quantum–classical optimization workflows to improve the fidelity and scalability of drug discovery pipelines. By encoding molecular interactions into parameterized quantum circuits, the framework leverages quantum superposition and entanglement to explore complex chemical space more efficiently, enabling refined estimation of binding energies and accelerated identification of high-quality leads. Preliminary simulations indicate that VQA-based estimators outperform classical baselines for challenging protein–ligand systems, reducing prediction error while maintaining computational tractability. These findings highlight the emerging potential of quantum technologies to enable more accurate, data-efficient, and mechanistically grounded drug discovery for next-generation therapeutics.

Next frontier.•Nov 28, 2025•0 citations

Molecular docking via quantum approximate optimization algorithm

Qi-Ming Ding, Yiming Huang, Xiao Yuan

Molecular docking plays a pivotal role in drug discovery and precision medicine, furnishing insights into protein functionalities and fostering the development of therapeutics. Here, we introduce a potential alternative solution to this problem using a quantum approximate optimization algorithm (QAOA) based algorithm. Our method was applied to analyze diverse biological systems, including the SARS-CoV-2 ${\mathrm{M}}^{\text{pro}}$ complex with PM-2-020B, the DPP-4 complex with piperidine fused imidazopyridine 34, and the HIV-1 gp120 complex with JP-III-048. We found that the digitized-counterdiabatic QAOA (DCQAOA), which integrates the concept of counterdiabatic driving, surpasses the conventional QAOA in terms of quantum circuit depth and optimization efficiency. This is particularly evident in complex molecular-docking challenges, where DCQAOA delivers more accurate and biologically relevant results. Our research highlights the promising role of quantum computing in drug discovery and contributes significant insights towards the optimization of protein-ligand docking methodologies.

arXiv:2308.04098•Physical Review Applied•Mar 19, 2024•54 citations

Synergistic Computational Approaches for Accelerated Drug Discovery: Integrating Quantum Mechanics, Statistical Thermodynamics, and Quantum Computing

Farzad Molani, Art E. Cho

Accurately predicting protein-ligand binding free energies (BFEs) remains a central challenge in drug discovery, particularly because the most reliable methods, such as free energy perturbation (FEP), are computationally intensive and difficult to scale. Here, we introduce a hybrid quantum-classical framework that combines Mining Minima sampling with quantum mechanically refined ligand partial charges, QM/MM interaction evaluation, and variational quantum eigensolver (VQE)-based electronic energy correction. This design enables explicit treatment of polarization, charge redistribution, and electronic correlation effects that are often underestimated in purely classical scoring schemes, while retaining computational efficiency. Across 23 protein targets and 543 ligands, the method achieves a mean absolute error of about 1.10 kcal/mol with strong rank-order fidelity (Pearson R = 0.75, Spearman rho = 0.76, Kendall tau = 0.57), consistent with the performance of contemporary FEP protocols. Notably, the workflow requires only about 25 minutes per ligand on standard compute resources, resulting in an approximate 20-fold reduction in computational cost relative to alchemical free energy approaches. This level of accuracy and efficiency makes the method well-suited for high-throughput lead optimization and iterative design cycles in pharmaceutical discovery. The framework also provides a natural foundation for future integration with machine learning models to enable predictive, large-scale, and adaptive screening strategies.

physics.chem-phCross-listedarXiv:2512.06141•Dec 9, 2025
Drug discovery is a resource-intensive process that often requires years of research and incurs high computational costs. Although classical machine learning (ML) has enhanced aspects of this process, its scalability is constrained by the exponential complexity of molecular interactions. Quantum computing (QC), with its inherent capabilities of superposition and entanglement, presents a transformative opportunity to overcome these limitations. Here, we introduce a novel Quantum Approximate Optimization Algorithm (QAOA)-based framework designed to efficiently compute protein-ligand binding energies which is a pivotal metric in rational drug design and precision medicine. By reformulating the binding energy problem as a MaxCut optimization, our approach achieves remarkable accuracy, with deviations of only ± 0.5kcal/mol relative to established classical methods such as funnel metadynamics. Furthermore, we demonstrate the robustness of the algorithm across various ligand topologies and protein conformations, highlighting its potential for scalable quantumaccelerated drug screening. This study advances the application of near-term quantum algorithms in computational chemistry and lays the foundation for future QC-driven breakthroughs in biomedical research. Our findings underscore the feasibility of quantumenhanced drug discovery, offering a pathway to significantly reduce the development timelines and costs while improving therapeutic precision.
The exorbitant costs, protracted timelines, and elevated attrition rates associated with traditional drug-discovery pipelines underscore the pressing necessity for computational frameworks that can elucidate biomolecular interactions with quantum-level precision and practical scalability. This study introduces a Hybrid Quantum Classical (HQC) framework that combines quantum variational algorithms, classical molecular dynamics, and quantum-assisted machine-learning optimization into a single drug-screening workflow. It builds on the basic idea of Quantum Molecular Simulation (QMS). In the suggested design, quantum processors are used to selectively fix high-fidelity electronic interactions in reactive binding sites, while classical engines model the large-scale conformational dynamics of biomolecular environments. An adaptive quantum-machine-learning layer speeds up convergence even more by learning how structure and energy are related from quantum-refined descriptors. Benchmark tests against oncogenic targets like EGFR, BCR-ABL1, and p53 show that our method is up to 27% more accurate at converging binding energy and takes 4.3 times less time to compute than standard density-functional-theory and standalone QMS methods. The HQC framework makes quantum drug simulation possible for real-world drug discovery by reducing the limitations of current quantum hardware while keeping electronic-scale accuracy. This study demonstrates that hybrid quantum-classical modeling is a scalable and hardware-compatible approach for advancing next-generation computational drug design and precision therapeutics.
The large search space and the challenge of accurately simulating quantum-level molecular interactions are the fundamental causes of the delayed, complicated, and costly process of discovering new medications. The effectiveness of conventional computational techniques, including molecular docking and molecular dynamics, to assess molecular characteristics and provide highly accurate drug candidate predictions is constrained. This paper presents a Quantum-Assisted Drug Discovery Simulation framework that combines cutting-edge quantum computing algorithms, specifically the Quantum Approximate Optimization Algorithm (QAOA) and the Variational Quantum Eigensolver (VQE), with traditional molecular docking tools like RDKit and AutoDock. The system uses these quantum algorithms to perform very accurate Quantum Refinement on the most potential therapeutic protein poses found by classical identification. This hybrid approach seeks to optimize drug-protein interactions more quickly, speed up early-stage drug discovery, and create opportunities for less costly, more accurate medical research, even though a combination of quantum and classical calculations allows more accurate prediction of molecular energies and binding affinities.
The drug discovery process has always been a problem for the pharmaceutical industry’s low rates of success, high expenses, and long-time frames. Quantum computing (QC) is being touted as a revolutionary advancement because of its unparalleled speed to carry out intricate multi molecular simulation and optimization. Unfortunately, its practical use has been suppressed due to the absence of proper hardware and the integration problems with traditional systems. Our solution is a quantum-classical pipeline for drug discovery. This pipeline utilizes machine learning (ML) for protein-ligand binding, drug property optimization, and even de novo drug design. In this paper we describe the pipeline, its components, the way it operates using NISQ devices, and the improvements it has in terms of accuracy and scalability (93.5% vs 78.2%) when compared with classical methods. Finally, we summarize how this can aid in modern drug discovery. It could significantly decrease the cost and timeline for pharmaceutical innovations.
Accurate prediction of binding affinities and efficient lead optimization remain central challenges in computational drug discovery, particularly for complex biological targets characterized by rugged energy landscapes, conformational heterogeneity, and high-dimensional interaction spaces. Classical computational methods—such as molecular docking, force-field–based simulations, and deep learning models—have made substantial progress, yet they often struggle to capture quantum-mechanical effects and long-range correlations critical to molecular recognition. This study explores a quantum-enhanced framework that integrates Variational Quantum Algorithms (VQAs), quantum-inspired Hamiltonian modeling, and hybrid quantum–classical optimization workflows to improve the fidelity and scalability of drug discovery pipelines. By encoding molecular interactions into parameterized quantum circuits, the framework leverages quantum superposition and entanglement to explore complex chemical space more efficiently, enabling refined estimation of binding energies and accelerated identification of high-quality leads. Preliminary simulations indicate that VQA-based estimators outperform classical baselines for challenging protein–ligand systems, reducing prediction error while maintaining computational tractability. These findings highlight the emerging potential of quantum technologies to enable more accurate, data-efficient, and mechanistically grounded drug discovery for next-generation therapeutics.
Molecular docking plays a pivotal role in drug discovery and precision medicine, furnishing insights into protein functionalities and fostering the development of therapeutics. Here, we introduce a potential alternative solution to this problem using a quantum approximate optimization algorithm (QAOA) based algorithm. Our method was applied to analyze diverse biological systems, including the SARS-CoV-2 Mpro{\mathrm{M}}^{\text{pro}}Mpro complex with PM-2-020B, the DPP-4 complex with piperidine fused imidazopyridine 34, and the HIV-1 gp120 complex with JP-III-048. We found that the digitized-counterdiabatic QAOA (DCQAOA), which integrates the concept of counterdiabatic driving, surpasses the conventional QAOA in terms of quantum circuit depth and optimization efficiency. This is particularly evident in complex molecular-docking challenges, where DCQAOA delivers more accurate and biologically relevant results. Our research highlights the promising role of quantum computing in drug discovery and contributes significant insights towards the optimization of protein-ligand docking methodologies.
Accurately predicting protein-ligand binding free energies (BFEs) remains a central challenge in drug discovery, particularly because the most reliable methods, such as free energy perturbation (FEP), are computationally intensive and difficult to scale. Here, we introduce a hybrid quantum-classical framework that combines Mining Minima sampling with quantum mechanically refined ligand partial charges, QM/MM interaction evaluation, and variational quantum eigensolver (VQE)-based electronic energy correction. This design enables explicit treatment of polarization, charge redistribution, and electronic correlation effects that are often underestimated in purely classical scoring schemes, while retaining computational efficiency. Across 23 protein targets and 543 ligands, the method achieves a mean absolute error of about 1.10 kcal/mol with strong rank-order fidelity (Pearson R = 0.75, Spearman rho = 0.76, Kendall tau = 0.57), consistent with the performance of contemporary FEP protocols. Notably, the workflow requires only about 25 minutes per ligand on standard compute resources, resulting in an approximate 20-fold reduction in computational cost relative to alchemical free energy approaches. This level of accuracy and efficiency makes the method well-suited for high-throughput lead optimization and iterative design cycles in pharmaceutical discovery. The framework also provides a natural foundation for future integration with machine learning models to enable predictive, large-scale, and adaptive screening strategies.